fluorobenzenes has been researched along with Angor Pectoris in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lucisano, L; Sardella, G | 1 |
| Badar, AA; Cleland, JG; Gardner, RS; Hawkins, NM; Jhund, PS; Kjekshus, J; McMurray, JJ; Perez-Moreno, AC; Petrie, MC; van Veldhuisen, DJ; Watkins, S; Wedel, H; Wikstrand, J; Wong, CM | 1 |
| Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Durmaz, T; Sen, N | 1 |
| Ahn, Y; Cho, JG; Choi, YH; Hong, YJ; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Ko, JS; Lee, MG; Ma, EH; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, NS; Youn, HJ | 1 |
| Fischer, G; Grohs, JG; Raberger, G | 1 |
| Conti, CR | 1 |
2 trial(s) available for fluorobenzenes and Angor Pectoris
| Article | Year |
|---|---|
Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
Topics: Aged; Angina Pectoris; Female; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Stroke Volume; Sulfonamides; Treatment Outcome; Ventricular Dysfunction, Left | 2014 |
Prevention of peri-procedural myocardial injury using a single high loading dose of rosuvastatin.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Biomarkers; Creatine Kinase, MB Form; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Intraoperative Complications; Male; Middle Aged; Myocardial Infarction; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Troponin I | 2010 |
4 other study(ies) available for fluorobenzenes and Angor Pectoris
| Article | Year |
|---|---|
High dose statins should be used in all patients undergoing percutaneous coronary intervention.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Female; Fluorobenzenes; Humans; Intraoperative Complications; Male; Myocardial Infarction; Pyrimidines; Sulfonamides | 2014 |
Impact of baseline plaque components on plaque progression in nonintervened coronary segments in patients with angina pectoris on rosuvastatin 10 mg/day.
Topics: Angina Pectoris; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Statistics, Nonparametric; Sulfonamides; Ultrasonography, Interventional | 2010 |
Verification of a canine model of transient exercise induced myocardial dysfunction: antianginal effects of flestolol, an ultra short acting beta adrenoceptor antagonist.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Blood Pressure; Disease Models, Animal; Dogs; Fluorobenzenes; Heart Rate; Myocardial Infarction; Physical Exertion; Propanolamines; Time Factors | 1990 |
Use of nitrates in unstable angina pectoris.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Drug Therapy, Combination; Fluorobenzenes; Hemodynamics; Humans; Infusions, Intravenous; Isosorbide Dinitrate; Nitroglycerin; Propanolamines | 1987 |